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In the last two decades, there has been a strong interest in searching for biological treatments for regeneration of injured
growth plate cartilage and prevention of its bony repair. Various means have been tried, including implantation of chondrocytes,
mesenchymal stem cell (MSC), together with exogenous growth factor and scaﬀolds, and gene therapy. However, with the lack
of success with chondrocytes, more research has focussed on MSC-based treatments. In addition to circumvent limitations with
MSC-based treatments (including cell harvest-associated morbidity, diﬃculties/time/cost involved in MSC isolation and ex vivo
expansion, and potential disease transmission), mobilising endogenous MSCs to the growth plate injury site and enhancing in
situ regeneration mechanisms would represent an alternative attractive approach. Further studies are required to investigate the
potential particularly in large animal models or clinical setting of the ex vivo MSC approach and the feasibility of the endogenous
MSC in situ approach in growth plate regeneration.
1. Introduction
Situated at the ends of all long bones, the growth plate
is solely responsible for the lengthening of long bones.
However, being of a cartilaginous nature, the growth plate is
highly susceptible to injuries. Depending on the severity and
location, often these injuries are often repaired undesirably
by bony repair tissue (also known as a bone bridge forma-
tion) which in turn often results in orthopaedic conditions
such as limb length discrepancies and bone angulation defor-
mities. As the current methods of correcting growth plate
injury-induced bone growth defects are surgically based,
highly invasive and not always successful, increasing interest
has been shown towards the development of biological
treatments which aim to promote growth plate cartilage
regeneration and prevent the faulty bony repair. However,
although a myriad of studies have investigated potential
therapeutic eﬀects of tissue-, chondrocyte-, growth factor-
, or mesenchymal stem cells-(MSC-) based approaches in
repairing injured growth plate with diﬀerent degrees of
success, currently there is not a biological therapy clinically
available that can induce growth plate regeneration. This
paper attempts to summarise previous and current research
investigating therapeutic potentials of various biological
materials or approaches with a particular focus on MSC-
based therapies in attempt to induce growth plate cartilage
regeneration.
2. The Growth Plate Cartilage
Children’s long bones contain a large cartilaginous region
known as the growth plate (epiphyseal plate) which is
responsible for the longitudinal growth of that particular
long bone, through chondrocyte proliferation, hypertrophy,
apoptosis, cartilage matrix synthesis, mineralization, and
vascularisation [1–3]. The area of this cartilaginous region
significantly decreases as the young person gets older and
it closes when the maximum growth of the long bone
is achieved. The region directly under the growth plate
is called the metaphysis which is where the mineralised
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growth plate cartilage is being replaced by bone, a process
called endochondral ossification [4]. Thus, endochondral
ossification bone lengthening is via a two-step process
that involves growth plate cartilage scaﬀold formation
and the diﬀerentiation and function of bone-forming cells
osteoblasts to initiate bone formation in the metaphysis
[1, 5].
3. Growth Plate Injury and Current Treatments
Due to accidents in sports and play, skeletal fractures
are common in children, with up to 50% children of 5–
18 years old experiencing a bone fracture [6]. Since the
growth plate is the least rigid region of the long bone,
its injuries are common, and it has been estimated that
around 20% childhood bone fractures involve growth plate
[7]. The Salter-Harris classification system has been used to
distinguish the diﬀerent types of growth plate injuries and
the relationship between the characteristics of the fractures
and their prognoses (Figure 1) [1, 8–10]. Current literature
indicates that the most common type of growth plate
fractures occurring in the distal tibiae of younger children is
type II (around 40%), which in most cases has a reasonably
good prognosis as the cells responsible for interstitial growth
of the growth plate as well as the epiphyseal blood supply
remain undisturbed [10–12]. Other types of fractures, types
III, IV, and V, however, may/will all result in bony formation
at the injured site [13]. It has been estimated that in up
to 30% of all children with growth plate-related injuries,
undesirable bony repair, and bone bridge at the injury
site hinder normal growth of the developing long bone
in the aﬀected limb [14, 15], which results in significant
orthopaedic problems such as limb length discrepancy and
bone angulation deformity [15, 16].
Due to the significant orthopaedic problems resulting
from growth plate injuries, many previous studies have
looked at diﬀerent ways of correcting growth plate injury-
induced defects as well as preventing the bony repair [17].
The type of treatment for growth plate injuries is largely
dependent on the age of the patient as well as the severity
and type of injury sustained [18]. Surgical intervention
is usually needed only if the patient is quite young and
significant growth remains. If the injury only results in
a very slight length discrepancy, it is often fixed through
the use of a shoe lift, and in most cases the patient must
cease using the aﬀected limb for a period of time in
order to prevent orthopaedic problems, such as angular
deformity, from occurring. An already established angular
deformity is commonly corrected with a wedge osteotomy
[19–21]. On the other hand, larger limb length discrepancies
require bone lengthening or bone shortening procedures
[22–24]. The most common way of correcting larger limb
length discrepancies is through a surgical and lengthening
procedure which surgically create a fracture at the diaphysis
and then gradually lengthens the injured limb to match
the growth of the unaﬀected limb using a large external
frame (Ilizarov frame) placed around the aﬀected limb [20,
23, 25]. As eﬀective as this method of treatment is, the
downside is that the procedure is highly invasive, painful
Salter-Harris classification
Normal Type I Type II
Type III Type IV Type V
Figure 1: The Salter-Harris classification system. Types I and II
fractures do not aﬀect the epiphyseal blood supply. On the other
hand, types III, IV, and V do disrupt the blood supply and will more
than often result in undesirable bony repair tissue-causing problems
of angulations and growth arrest.
and lengthy. As only a limited amount of lengthening can
be done at a time, the patient often requires the procedure
several times throughout adolescence until skeletal maturity
is reached. Furthermore, complications arising from pin site
infections, further fractures, dislocation, and compartment
syndromes make this procedure even more diﬃcult [26].
More recently, another technique has been introduced which
can be used to lengthen the aﬀected limb involving the use
of an implantable and programmable distraction internal
nail known as “Fitbone” for adolescents who have reached
maximal growth [27]. Fitbone eliminates the need for an
external fixator and hence has the potential to reduce pain
and the risk of infections occurring within the treatment site.
Sometimes, an established bone bridge can be surgically
removed for correction of growth defects. In order to prevent
growth arrest and angulation deformity from recurring, the
defect site can be filled with transplanted fat, muscle, poly-
meric silicone, bone wax, and bone cement as interposition
materials [17]. This procedure is called the Langenskiold
method [28]. However, all of these available treatments
so far are extremely invasive, time consuming, and often
ineﬀective. Currently, much interest has been drawn in
finding a better treatment (particularly by a preventative
biological approach) to prevent and/or correct problems
associated with bony bridge formation. In particular, inmore
recent times, more research has focussed on utilising tissue
engineering and the use of mesenchymal stem cells (MSC)
for the regeneration of growth plate cartilage.
4. Previous Attempts with
Chondrocyte/Cartilage Transplantation
This void or deficiency of a biological treatment for growth
plate injuries has instigated many medical scientists and
clinicians to find a potential biological therapy which is able
to prevent the bony repair at the injured growth plate and
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hence thwart the serious orthopaedic problems associated
with this condition. Ideally, a successful therapy would have
the ability to regenerate the growth plate cartilage so that
the long bone is able to grow with minimal disruption
minimising any angulation and/or growth arrest of the
aﬀected limb. However, as with any cartilaginous structures
the transphyseal growth plate injuries are very hard to heal
to the original state as chondrocytes are very diﬃcult to
regenerate [29, 30].
Allogeneic and autologous chondrocyte transplantations
are one potential approach to overcome this problem,
and both methods of chondrocyte transplantation have
previously been utilised or trialled for articular cartilage
or growth plate repair studies. Allogeneic chondrocyte
transplantation involves the removal of healthy chondrocytes
from one source followed by the ex vivo expansion and
finally the replantation of the expanded chondrocytes into
another individual (of the same species) [31]. However, the
disadvantages of this procedure involve the risk of disease
transmission between the two individuals. Alternatively,
autologous chondrocyte transplantation involves the direct
harvest of healthy chondrocytes (often from the knee) which
are then cultured and expanded ex vivo; unlike the allogeneic
approach, the chondrocytes are implanted back into the
patient at the location of the defect, therefore, eliminating
any risks of disease transmission [32]. Nevertheless, the
disadvantage of this method is the time frame taken to
collect, expand, and reimplant the chondrocytes, which has
been estimated 3 weeks [33]—by which time, in the case
of growth plate injury—a bone bridge has already started
to form, thus eliminating this autologous chondrocyte
transplantation approach being feasible for growth plate
regeneration.
Although there have been many successful studies which
have used the allogeneic and autologous chondrocyte trans-
plantation approach for articular cartilage regeneration, very
few studies have been performed on growth plate injury
models. One earlier study, Bentley and Greer [34] found
some success when allogeneic chondrocytes (collected from
the growth plate) were delivered into the growth plate injury
site of White New Zealand rabbits. This study reported that
chondrocytes filled the defect and were able to form columns.
In addition, although there were signs of endochondral
ossification at the base of the injury site, no rejection of
the implanted chondrocytes occurred [34]. However, one
study, using a large animal (sheep) tibial growth plate
injury model, attempted transplanting chondrocytes directly
into the growth plate injury site and did not produce
any successful outcomes in preventing the bony bridge
formation [35]. Hence, this highlights the unlikelihood of
achieving successful growth plate cartilage regeneration with
this chondrocyte transplantation approach.
5. Recent Attempts with MSC-Based Growth
Plate Cartilage Repair
Due to the limitations associated with chondrocyte trans-
plantation including instability during expansion and donor
tissue availability as well as outcome success [36], an
alternative cell source, that has been heavily investigated,
has been the stem cells. Being of an undiﬀerentiated type,
embryonic stem cells hold great potential in diﬀerentiation
and successful tissue engineering; however, the myriad of
ethical and potential health risks and dilemmas involved with
their use deem them almost inaccessible [37]. On the other
hand, adult mesenchymal stem cells (MSC) are renewable,
undiﬀerentiated pluripotent cells which are also capable of
diﬀerentiating into many diﬀerent cell types [38] such as
cartilage, bone, and fat cells.
MSCs are abundant and have been successfully iso-
lated from many sources including bone marrow [39, 40],
periosteum [41–43], trabecular bone [44, 45], adipose tissue
[46–48], skeletal muscle [49, 50], and synovium [51–53].
Due to their pluripotency, abundance and accessibility, bone
marrow-derived MSCs have made a particularly attractive
source for use in articular and growth plate cartilage
regeneration [5, 22, 39, 54]. Additionally, an in vivo study
done by Park et al. [55] showed that MSCs derived from
bone marrow and perichondrium/periosteum were more
successful at forming hyaline cartilage than from those MSCs
derived from other sources such as adipose tissue [55].
Although bone marrow-derived MSCs make up a small
proportion of total marrow nucleated cells, they can be
easily isolated and expanded with high eﬃciencies [36]. A
plethora of bone marrow-derived MSC related studies have
demonstrated the ability of MSCs to diﬀerentiate in vitro
into multiple cell lineages depending on defined culture
conditions including diﬀerentiation into chondrocytes [40,
54, 56]—making them an ideal candidate for use in articular
cartilage repair and potentially for growth plate cartilage
repair. In addition, MSCs have also been documented as
possessing unique immunosuppressive properties which are
advantageous during procedures such as transplantation
[57, 58]. Furthermore, it has been hypothesized that bone
marrow-derived MSCs secrete various factors which are
bioactive with the ability to inhibit scar tissue formation,
suppress apoptosis, stimulate angiogenesis [59], as well as
having immunoregulatory and regenerative properties [60–
62] in comparison to MSC derived from other sources.
Using a growth plate injury model in rabbits, Chen
et al. [63] successfully transplanted periosteum-derived
MSCs into the growth plate defect and found that the high-
proliferation rate of MSCs made them an excellent source
for donor cells [63]. Similar to chondrocyte transplantation,
two potential methods of delivering MSCs into the desired
area of injury is via autologous or allogeneic transplantation.
Autologous transplantation of MSCs involves the harvesting
of patients’ own MSCs and then reimplantation after ex vitro
expansion. On the other hand, allogeneic transplantation
of MSCs involves the use of MSCs taken directly from
a cell bank. Planka et al. [64] compared the diﬀerences
between autologous and allogeneic MSC transplantation and
found that there were no major diﬀerences in the eﬀect of
these implanted MSCs on tibia length and potential angular
deformities [64]. Furthermore, the implantation of these
cells saw the formation of hyaline chondrocytes within the
growth plate injury site [64]. This result was also seen when
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allogeneic MSCs were transplanted into the site of growth
plate injury in a guinea pig model [65].
It is not guaranteed that implanted MSC will change into
the desirable chondrocytes. The diﬀerentiation of MSCs is
highly dependent on cellular environment, hence, is heavily
influenced by the presence of certain growth factors [66].
To optimise the expansion and chondrogenesis of MSCs for
cartilage repair, certain growth/survival, and chondrogenic
factors need to be present in order to stimulate themigration,
growth, survival and chondrogenic potentials of MSCs or
progenitor cells. There have been many previous studies
which have identified some stimuli or signal molecules con-
trolling their migration, proliferation (PDGF-BB, FGF-2),
and chondrogenic diﬀerentiation (TGF-β1, IGF-I). PDGF-
BB has long been found to be an important growth and
survival factor of MSCs [54, 67], and FGF-2 has been shown
to enhance mitotic and chondrogenic potentials of human
bone marrow-derived MSCs in culture [68]. TGF-β3 has
been shown to stimulate chondrogenic diﬀerentiation in
MSCs and expression of cartilage matrix molecules [69, 70].
In support, Anh et al. [71] found that in young New Zealand
White rabbits with growth plate defects, gelfoam (porcine
skin gelatin) with MSC, as well as TGF-β3 was found to
have remarkably reduced the angular deformity following
injury repair [71]. On the other hand, one more recent
study which used similar methods in an ovine tibial growth
plate injury model did not produce successful cartilage
regeneration outcome at the injured growth plate (which is
in contrast to the their rabbit model) [72]. However, the
study found the addition of theMSCs/growth factor/gelfoam
complex did not alter the rate of bony repair formation [72].
In addition, IGF-I has been found to be essential for the
diﬀerentiation andmaturation of growth plate chondrocytes,
with important anabolic eﬀects on matrix production for
maintaining articular cartilage homeostasis. Furthermore, it
has been shown that the structural, functional, and molec-
ular properties of engineered cartilage can be modulated by
sequential application of growth factors [54]. While TGF-β
stimulates MSC chondrogenesis and IGF-I can enhance their
extracellular matrix synthesis, the combined stimulatory
eﬀects of TGF-β1 and IGF-I may form a potentially valuable
dual stimulatory eﬀect on intrinsic or transplanted MSC
function. Such combined stimulatory eﬀects have been
demonstrated in the chondrogenesis of periosteum MSCs
in vitro [69]. Overall from the few studies which focus on
combined eﬀects of growth factors and MSC implantation,
supplementation with an appropriate growth factor or
combination of growth factors is important for a successful
outcome for MSC-based growth plate cartilage regeneration.
However, further studies are required exploring potential,
more potent growth factors, their optimal delivery and
formulation for enhancing success for MSC use in cartilage
engineering.
Without the correct support and environment, studies
have shown that newly injected MSCs were not able to
be viable for a suﬃcient length of time [73]. Therefore,
similar to chondrocyte transplantation, to increase longevity
and activity, to encourage chondrogenesis as well as to
direct the transplanted MSCs into the desired area, a sup-
porting scaﬀold made from an appropriate material is
needed. A myriad of natural and synthetically produced
materials have been studied such as fibrinogen, collagen,
collagen derivatives, as well as various man-made polymers
and other synthetic biomaterials. Di Martino et al. [74]
outlined several important qualities when developing the
ideal scaﬀold including biocompatibility, bioabsorbability/
biodegradability, appropriate pore size, as well as providing
a stable foundation for new tissue formation—in particular
suitable for MSC growth, proliferation, and chondrogenesis
[74]. Currently, many studies which have reported success
in MSC transplantation and diﬀerentiation use scaﬀolds of
various types made of natural substances. Natural substances
are biologically more compatible and biodegradable, and
they provide a more natural microenvironment for the
embedded MSCs [59]. Some of the commonly used natural
materials are both protein and carbohydrate-based, includ-
ing chitosan, collagens, fibrin gels, hyaluronan, and alginate
[47, 75–80].
Some of the more commonly researched natural mate-
rials for use in cartilage regeneration in growth plate and
articular cartilage studies include chitosan and fibrin gels.
Planka et al. [64] embedded MSC into a scaﬀold of chitosan
and collagen and placed the complex into the growth plate
injury site of miniature pigs. The gel scaﬀold was able to
be sealed with a bioceramic material to stop cells from
deviating from the desirable area which resulted in some
success in preventing growth arrest and angulation deformity
[65]. Similarly, an earlier study conducted by Li et al.
[81] reported their chitosan-MSC construct was able to
restore large growth plate defects in immature rabbits [81].
Medrado et al. [82] also reported the benefits of a chitosan-
gelatine construct in vivo, whereby the addition of MSCs and
dexamethasone resulted in an increase of cell adhesivity, pro-
liferation as well as cell viability. Interestingly, the addition
of dexamethasone found an increase in the concentration
of collagen-2a when combined with the chitosan-gelatine-
MSC complex [82]. Apart from chitosan, a few studies have
used materials such as agarose—a polysaccharide obtained
from agar. Chen et al. [63] did a large growth plate defect
study on a 6-week-old NZW rabbits using agarose with
embedded MSCs harvested from the periosteum. Chen
et al. [63] found that growth arrest and angular deformation
and loss of length of tibia induced by the growth plate
defect were corrected by the MSC-agarose treatment in com-
parison to agarose-only controls [63]. In addition to these
naturally occurring substances, synthetic materials such as
poly (lactic-co-glycolic acid) (PGLA) and poly (lactic acid)
(PGA) have also been used for cartilage tissue engineering.
Unlike chitosan and other natural substances, these synthetic
counterparts allow modifications such as pore size, fibre
diameter, and degradation properties to suit their specific
use. Previous studies have found some success in using these
synthetic materials for articular cartilage regeneration [83–
85]. However, some of the limitations associated with their
use include relatively poor cell adhesion properties as well as
issues concerning their biocompatibility [86].
In recent times, the development of injectable hydrogels
has become of great interest for cartilage repair and poten-
tially growth plate cartilage regeneration. These are gel-like
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substances which can have MSC embedded into them [87].
Hydrogels oﬀer the administration of growth factors and/or
cells into a cartilage defects more accessible and easier. Cho
et al. [88] have developed alginate/polyvinyl alcohol (PVA)
hydrogels which is able to gelatinize at a more controllable
rate than solely alginate hydrogels. Future studies will reveal
potential of MSCs alongside these natural and injectable
scaﬀolds and the appropriate growth factors to regenerate
articular and growth plate cartilage.
6. Combined MSC and Gene Therapy Approach
for Cartilage Repair
Successful chondrogenic regeneration involves two key
points—first, to encourage chondrogenesis, and second to
form new cartilage. Although current studies have provided
a myriad of diﬀerent bioactive factors that have potential to
greatly benefit the repair process, diﬃculties associated with
their administration have slowed down any real progress.
This explains why new techniques involving methods such
as genetic engineering and gene transfer technology have
become of interest. Although a majority of these studies were
not done specifically for repairing growth plate cartilage,
many of the techniques could potentially be applied for this
use. Successful gene transfer can be achieved through a few
diﬀerent approaches: the direct vector administration to cells
or surrounding cells within the injury site or alternatively and
the transplantation of genetically modified chondrogenic
cells into the aﬀected area [89].
Direct modification of ex vivo chondrocytes has been
well studied. Cultured chondrocytes were able to maintain
the expression of certain transgene products after genetic
modification with recombinant adenoviral of TGF-β [90,
91], BMP-7 [92], and IGF-I [91, 93]. Nixon et al. [93]
found that in vitro experiments involving the adenoviral
over expression of IGF-I in chondrocytes resulted in the
stimulated expression of proteoglycans as well as collagen
type 2 [93]. Proteoglycan and collagen type 2 synthesis were
also stimulated when TGF-β1 was transduced adenovirally
on a monolayer of chondrocytes [90, 91]. In more recent
times, interest has been shown for the gene transfer of
transcriptional factors such as Sox-9. Sox-9 is a known
master regulator of chondrogenesis, hence when Sox-9 was
retrovirally overexpressed, it resulted in increased collagen
type 2 expression in a pellet culture [94].
Since treatment with growth factors is often not suc-
cessful due to the short half-life of many growth factors,
and since gene delivery is a better alternative to deliver
growth factors because it is more stable and flexible than the
protein itself [95], much interest has been drawn towards
genetic modification of MSCs with growth factor genes
for enhancing cartilage repair. This technique requires the
ex vivo genetic modification of MSCs followed by the
transplantation of the altered cells back into the aﬀected area
[59]. Since modification by any means is an alteration of
the original, Hu et al. [96] questioned whether gene-altered
MSCs were still capable of possessing their characteristic
of multipotency [96]. They found that after retroviral
transfection with human IGF-I, rat MSCs showed a greater
ability to express IGF-I as well as an increased ability to
proliferate and reduce apoptosis, and that modifications
of MSCs could potentially aﬀect the types of tissues they
diﬀerentiate into [96]. In order to lengthen the time and
versatility of MSCs, Song et al. [97] utilised gene therapy
to transfect bone marrow-derived MSCs with the FGF-2
gene, which showed an improvement in survival of MSC
against hypoxic conditions in vitro [97]. In addition, another
study also modifiedMSCs with angiogenin adenoviral vector
which resulted in the enhancement of implanted cells against
hypoxic injury [98].
Although there are many studies which have successfully
transduced MSCs with variety of chondrogenic growth
factors, an interesting study discussed some of the limitations
of this MSC + gene therapy approach for cartilage repair.
A study by Palmer et al. [99] showed that only a certain
amount of gene expression was needed to induce chon-
drogenic diﬀerentiation of bone marrow-derived cells, and
that overexpression by gene-induced transduction may have
negative, opposing eﬀect on chondrogenic diﬀerentiation
[99]. In addition, a few other disadvantages of the ex vivo
approach for gene therapy include high cost and being
fairly laborious and time consuming. However, ex vivo gene
therapy allows the safety testing and control of the cells
before the reimplantation and hence minimising any risk of
disease transmission [100]. Overall, although the potential
of combining gene therapy techniques with MSCs has been
more recently explored, not many have applied it to the
regeneration of growth plate cartilage. Hence, further studies
are needed to investigate whether this type of cartilage
engineering is useful in growth plate cartilage regeneration.
7. Endogenous Stem Cell Possibility
Although a number of studies with rabbit growth plate
injury repair models have shown that MSCs may have
some potential in regenerating injured growth plate and
prevent bone growth defects [63–65, 71]. However, recent
work with a large animal model has questioned value of
this ex vivo MSC approach [72]. While ovine bone marrow
MSCs are multipotential and can form cartilage-like tissue
in vivo [101], however, in a growth plate injury model in
lambs, autologous bone marrow-derived ex vivo-expanded
MSCs failed to promote growth plate regeneration [72].
In addition, currently, MSC-mediated cell therapies are
limited by various diﬃculties and issues such as morbidity
associated with cell harvest, diﬃculty in stem cell isolation,
genetic and phenotypic instability associated with ex vivo
expansion, diﬃcult up-scaling, high costs, variability, and
risks of disease transmission particularly with allogeneic
MSC transplantation [54]. While transplantation of both
allogeneic and autogenous MSC as well as modified MSCs
oﬀer many advantages in cartilage repair, a major problem
associated with their use is the need for fetal calf serum
during ex vitro expansion.
The existence of functional stem cells within the local
environment and their migratory capacity represent an
opportunity to circumvent limitations of ex vivo-based
MSC therapy and to achieve in situ cartilage regeneration
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by enhancing local reparative mechanisms and mobilis-
ing endogenous MSCs [52, 102]. MSCs express adhesion
molecules [103] and can migrate to sites of injury healing
[51, 97]. Indeed, synovial mesenchymal cells migrate to
cartilage defects and may serve as a cell source for repair
under specific growth factor stimulation [104], and marrow
MSC migrate and contribute to cartilaginous formation
during bone healing and contribute to articular repair [105].
Although present in small quantities during the fibro-
genic infiltrate with the growth plate injury site, endoge-
nous multipotent mesenchymal stromal cells were observed
during growth plate injury repair [106]. These cells demon-
strated their multipotency—diﬀerentiating into bone and
cartilage tissues within the injury site [67, 106–110]. With
infiltration of progenitor cells into growth plate injury site,
it will be of particular interest to investigate whether these
endogenous progenitor cells can be mobilised to enhance
growth plate regeneration.
However, the main problem with accessing the endoge-
nous cells for example from the bone marrow is that they
may not be present in a density large enough to support
adequate cartilage regeneration. Hence, to overcome this
problem, a recent study has suggested that selected growth
factors are needed to stimulate and enhance MSC migration
and accumulation into the cartilage injury site [111]. Dar et
al. [112] found the chemokine/receptor pair SDF-1/CXCR4
is present and functional in MSC population [112]. Kitaori
et al. [113] found that inhibition or absence of this signaling
resulted in absence of MSC in a bone fracture model [113].
In addition to the SDF-1/CXCR4 signalling, Schenk et al.
[114] reported monocyte chemotactic protein (MCP-3) as
another homing chemotactic signaling pathway for MSC
migration. Schenk et al. [114] found that in myocardial
infarction, the systemic infusion of this protein resulted in
a MSC migration response. Furthermore, Ode et al. [115]
studied roles and influences of diﬀerent extracellular matrix
components onMSCmigration and behavior and found that
the collagen family excluding collagen-V as well as adhesion
proteins such as fibronection and vitronectin all influenced
and encouraged the migratory and proliferatory behavior
of MSCs [115]. More studies are required to study how
endogenous MSCs can be regulated to enhance migration
into and expansion within the injury site for cartilage
regeneration.
8. Conclusion
Growth plate injuries are common in children and their
“faulty” bony repair impairs bone growth and cause life-
long orthopaedic problems. Current treatments (surgical
correction) for these problems are highly invasive and
often requiring repeated surgeries, and thus there is a
strong need for a biological treatment that can promote
growth plate cartilage regeneration. Although the approach
of using ex vivo expanded MSC has shown some promise
in promoting growth plate repair in rabbit models, the
eﬃcacy of this approach has been questioned in a recent
“translational study” using a large animal model. Further
studies are required to define more potent chondrogenic
growth factor(s) or matrix scaﬀold that will enhance growth
plate regeneration using ex vivo-expanded MSC, and more
studies are needed to investigate the therapeutic potential of
MSCs for growth plate regeneration in large animal models.
In addition, due to the time (around 3 weeks) required for
MSC isolation and expansion, this ex vivo approach with
autologous MSC may not be practical to treat a growth
plate shortly after the fracture; further studies are required
to investigate whether endogenous MSCs or progenitor
cells within the local environment or bone marrow can be
mobilised and local regenerative mechanisms be optimised
to achieve in situ growth plate regeneration after a growth
plate fracture so to circumvent limitations of ex vivo-based
MSC therapy.
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